Key Points Question Does a regimen of hydroxychloroquine, 600 mg, per day, reduce the transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a pre-exposure prophylaxis strategy when taken by hospital-based health care workers? Finding In this double-blind, placebo-controlled randomized clinical trial that included 132 participants and was terminated early, there was not a significant difference in reverse-transcriptase polymerase chain reaction–confirmed SARS-CoV-2 incidence between hydroxychloroquine and placebo cohorts. Meaning Among hospital-based health care workers, daily hydroxychloroquine did not prevent SARS-CoV-2 infection, although the trial was terminated early and may have been underpowered to detect a clinically important difference. Importance Health care workers (HCWs) caring for patients with coronavirus disease 2019 (COVID-19) are at risk of exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, to our knowledge, there is no effective pharmacologic prophylaxis for individuals at risk. Objective To evaluate the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in hospital-based HCWs with exposure to patients with COVID-19 using a pre-exposure prophylaxis strategy. Design, Setting, and Participants This randomized, double-blind, placebo-controlled clinical trial (the Prevention and Treatment of COVID-19 With Hydroxychloroquine Study) was conducted at 2 tertiary urban hospitals, with enrollment from April 9, 2020, to July 14, 2020; follow-up ended August 4, 2020. The trial randomized 132 full-time, hospital-based HCWs (physicians, nurses, certified nursing assistants, emergency technicians, and respiratory therapists), of whom 125 were initially asymptomatic and had negative results for SARS-CoV-2 by nasopharyngeal swab. The trial was terminated early for futility before reaching a planned enrollment of 200 participants. Interventions Hydroxychloroquine, 600 mg, daily, or size-matched placebo taken orally for 8 weeks. Main Outcomes and Measures The primary outcome was the incidence of SARS-CoV-2 infection as determined by a nasopharyngeal swab during the 8 weeks of treatment. Secondary outcomes included adverse effects, treatment discontinuation, presence of SARS-CoV-2 antibodies, frequency of QTc prolongation, and clinical outcomes for SARS-CoV-2–positive participants. Results Of the 132 randomized participants (median age, 33 years [range, 20-66 years]; 91 women [69%]), 125 (94.7%) were evaluable for the primary outcome. There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo (4 of 64 [6.3%] vs 4 of 61 [6.6%]; P > .99). Mild adverse events were more common in participants taking hydroxychloroquine compared with placebo (45% vs 26%; P = .04); rates of treatment discontinuation were similar in both arms (19% vs 16%; P = .81). The median change in QTc (baseline to 4-week evaluation) did not differ between arms (hydroxychloroquine: 4 milliseconds; 95% CI, −9 to 17; vs placebo: 3 milliseconds; 95% CI, −5 to 11; P = .98). Of the 8 participants with positive results for SARS-CoV-2 (6.4%), 6 developed viral symptoms; none required hospitalization, and all clinically recovered. Conclusions and Relevance In this randomized clinical trial, although limited by early termination, there was no clinical benefit of hydroxychloroquine administered daily for 8 weeks as pre-exposure prophylaxis in hospital-based HCWs exposed to patients with COVID-19. Trial Registration ClinicalTrials.gov Identifier: NCT04329923 This randomized clinical trial evaluates the efficacy of hydroxychloroquine to prevent transmission of SARS-CoV-2 in health care workers with exposure to patients with COVID-19 at 2 hospitals in Philadelphia, Pennsylvania.
【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, randomized clinical trial, Coronavirus disease 2019, Efficacy, coronavirus, clinical trial, Health care, Trial, Hydroxychloroquine, Hospitalization, knowledge, SARS-COV-2 infection, hospital, health care workers, risk, Transmission, prevention, outcome, severe acute respiratory syndrome Coronavirus, clinical outcomes, hospitals, Clinical outcome, Prophylaxis, adverse effects, Nurses, Registration, Randomized, Nasopharyngeal swab, Health, SARS-CoV-2 antibodies, Viral, Asymptomatic, HCWs, reverse-transcriptase polymerase chain reaction, adverse event, Patient, Health care worker, Placebo, Physicians, Philadelphia, Follow-up, infection rate, women, incidence, respiratory, Care, QTc, placebo-controlled, QTC prolongation, Frequency, double-blind, HCW, regimen, exposure to, determined by, ARMS, acute respiratory syndrome, Participants, Enrollment, Primary outcome, significant difference, Trial registration, 95% CI, acute respiratory syndrome coronavirus, no significant difference, acute respiratory syndrome coronavirus 2, Secondary outcomes, infection rates, median age, individual, positive result, futility, clinical benefit, measure, cohorts, placebo-controlled clinical trial, Identifier, participant, finding, transmission of SARS-CoV-2, pharmacologic prophylaxis, Administered, Arm, objective, Prevent, effective, setting, secondary, polymerase chain, Result, not differ, detect, evaluate, clinically, required, conducted, median, per day, reduce, Importance, receive, baseline, patients with COVID-19, Point, prophylaxis strategy, Relevance, SARS-CoV-2–positive, 【제목키워드】 SARS-CoV-2, Health care, Hydroxychloroquine, Safety, clinical, worker,